Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Arqués, Oriol; Chicote, Irene; Puig, Isabel; P. Tenbaum, Stephan; Argilés, Guillem; Dienstmann, Rodrigo; Fernández, Natalia; Caratù, Ginevra; Matito, Judit; Silberschmidt, Daniel; Rodón, Jordi; Landolfi, Stefania; Prat, Aleix; Espín, Eloy; Charco, R.; Nucíforo, Paolo; Vivancos, Ana; Shao, Wenlin; Tabernero, Josep; G. Pálmer, Héctor

doi:10.1158/1078-0432.ccr-14-3081

Public

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Published in Clinical Cancer Research • Jul 29, 2015

Authors:

Oriol Arqués

Irene Chicote

Isabel Puig

Abstract

PURPOSE: Oncogenic mutations in the KRAS/PI3K/AKT pathway are one of the most frequent alterations in cancer. Although PI3K or AKT inhibitors show promising results in clinical trials, drug resistance frequently emerges. We previously revealed Wnt/β-catenin signaling hyperactivation as responsible f...

Subject

Wnt signaling pathway

PI3K/AKT/mTOR pathway

KRAS

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!